• Phare
  • Validé par KD/KO

Anticorps Polyclonal de lapin anti-PD-L1/CD274 (C-terminal)

PD-L1/CD274 (C-terminal) Polyclonal Antibody for IHC

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

IHC

Conjugaison

Biotin

Publications(1)

N° de cat : Biotin-28076

Synonymes

B7 H, B7 H1, B7 homolog 1, B7H1, CD274, CD274 molecule, PD L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed death ligand 1



Applications testées

Résultats positifs en IHCtissu d'amygdalite humain, tissu placentaire humain
il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

ApplicationDilution
Immunohistochimie (IHC)IHC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

Biotin-28076 cible PD-L1/CD274 (C-terminal) dans les applications de IHC et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Réactivité citéesouris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène PD-L1/CD274 (C-terminal) Protéine recombinante Ag27557
Nom complet CD274 molecule
Masse moléculaire calculée 290 aa, 33 kDa
Poids moléculaire observé 45-50 kDa
Numéro d’acquisition GenBankBC074984
Symbole du gène PD-L1
Identification du gène (NCBI) 29126
Conjugaison Biotin
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA
Conditions de stockageStocker à -20 °C. Éviter toute exposition à la lumière. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA.

Informations générales

PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis. 

What is the molecular weight of PD-L1? 

Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176-290 aa). 

What are the isoforms of PD-L1? 

According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions. 

What is the subcellular localization and tissue specificity of PD-L1? 

It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues. 

What is the function of PD-L1 in immune responses? 

PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681). 

How can PD-L1's implication in cancer be used as a drug target? 

In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375).


Protocole

Product Specific Protocols
IHC protocol for Biotin PD-L1/CD274 (C-terminal) antibody Biotin-28076Download protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
mouse

ACS Appl Mater Interfaces

Harnessing Spatiotemporal-Specific Tumorous Exosome Dynamics: Ultra-Sensitive Lanthanide Luminescence Detection Strategy Enabled by Exosomal Membrane Engineering for Melanoma Immunotherapy Monitoring

Authors - Nanhang Zhu
{{ptg:RelatedPrimaryAntibodies}}